RedHill Biopharma (RDHL) Equity Average (2014 - 2025)

RedHill Biopharma (RDHL) reported Equity Average of -$72000.0 for Q4 2025, up 98.42% quarter-over-quarter from -$4.5 million in Q2 2025.

RedHill Biopharma (RDHL) Equity Average (2014 - 2025) Analysis & Trends

RedHill Biopharma (RDHL) has 2 years of Equity Average data on file, last reported at -$72000.0 in Q4 2025.

Equity Average for Q4 2025 came in at -$72000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was -$72000.0 (changed N/A YoY), and the FY2025 annual result was -$207500.0, up 84.12% from the prior year.
Equity Average rose to -$72000.0 in Q4 2025 per RDHL's latest filing, from -$4.5 million in the prior quarter.
Over five years, Equity Average peaked at -$72000.0 in Q4 2025 and troughed at -$4.5 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Avg. (Qtr)
1	Teva Pharmaceutical Industries	38.34 Bn	34.60 Bn	1.97 Bn	8.07 Bn
2	Zoetis	33.27 Bn	31.33 Bn	1.62 Bn	3.32 Bn
3	United Therapeutics	23.75 Bn	21.60 Bn	648.10 Mn	6.50 Bn
4	Aurora Cannabis	17.11 Bn	17.03 Bn	33.43 Mn	409.63 Mn
5	Neurocrine Biosciences	16.37 Bn	15.05 Bn	800.70 Mn	3.33 Bn
6	Elanco Animal Health	11.78 Bn	11.35 Bn	785.00 Mn	6.52 Bn
7	Alkermes	7.05 Bn	6.54 Bn	-116.06 Mn	1.79 Bn
8	Lantheus Holdings	6.49 Bn	5.99 Bn	230.92 Mn	1.15 Bn
9	Hims & Hers Health	6.19 Bn	5.44 Bn	396.79 Mn	493.55 Mn
10	RedHill Biopharma	142.34 Mn	142.34 Mn	-	-72,000.00

Download Data